Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 8/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14756115 | 0.84 | CHRM2 (0.53) | HTR1BCHRM2CHRM1CHRM3CYP2A6 | |
| SCHEMBL31061981 | 0.84 | CHRM2 (0.53) | HTR1BCHRM2CHRM1CHRM3CYP2A6 | |
| SCHEMBL31164857 | 0.83 | CA2 (0.55) | HTR1BCA12CA1CA2CA3 | |
| SCHEMBL111709 | 0.83 | CA2 (0.55) | HTR1BCA12CA1CA2CA3 | |
| Hydrochloric Acid SCHEMBL20563057 | 0.82 | CHRM2 (0.51) | HTR1BCHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL957248 | 0.79 | HTR1B (0.53) | HTR1BCHRM2CHRM1CHRM3CA12 | |
| SCHEMBL4328740 | 0.79 | HTR1B (0.53) | HTR1BCHRM2CHRM1CHRM3CA12 | |
| SCHEMBL17613378 | 0.79 | HTR1B (0.53) | HTR1BCHRM2CHRM1CHRM3CA12 | |
| SCHEMBL28033156 | 0.79 | HTR1B (0.53) | HTR1BCHRM2CHRM1CHRM3CA12 | |
| SCHEMBL25742666 | 0.79 | HTR1B (0.53) | HTR1BCHRM2CHRM1CHRM3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754705-A2 | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | Genentech, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| CN-115707698-A | 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-formamide compound, and preparation method and application thereof | 辽宁何氏医学院 | 2023-02-21 | — | — | CN | disclosed |
| US-20210198254-A1 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-07-01 | — | — | US | disclosed |
| US-10919888-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2017049321-A1 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | MILLER MARVIN J (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-1754705-A2 | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | Genentech, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1063982-B1 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH INC (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050203135-A1 | Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders | GENENTECH, INC. | 2005-09-15 | — | — | US | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1063982-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | Genentech, Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999049856-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | HTR1B 9/4885CHRM2 572/4885CHRM1 458/4885 |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | HTR1B 2581/4885CHRM2 3296/4885CHRM1 2893/4885 |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | HTR1B 3952/4885CHRM2 4166/4885CHRM1 3716/4885 |
| US-20050203135-A1 | Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders | VCAM1, CD58, ITGB8 | HTR1B 428/4885CHRM2 726/4885CHRM1 272/4885 |
| US-10919888-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | HTR1B 2581/4885CHRM2 3296/4885CHRM1 2893/4885 |
| US-20210198254-A1 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | BET1, BRD4, BRD3 | HTR1B 2581/4885CHRM2 3296/4885CHRM1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.